| Title |
Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
|
|---|---|
| Published in |
Current Oncology Reports, February 2011
|
| DOI | 10.1007/s11912-011-0154-3 |
| Pubmed ID | |
| Authors |
Pankaj Bhargava, Murray O. Robinson |
| Abstract |
The vascular endothelial growth factor (VEGF) signaling pathway appears to be the dominant pathway involved in tumor angiogenesis, providing a rationale for targeting the VEGF receptors (VEGFR-1, -2, and -3) in the treatment of cancers. In particular, VEGF signaling is thought to be important in renal cell carcinoma (RCC) because of the deregulation of the pathway through nearly uniform loss of the von Hippel Lindau protein. The tyrosine kinase inhibitors (TKIs) sorafenib, sunitinib, and pazopanib are approved by the US Food and Drug Administration for the treatment of advanced RCC; however, these multitargeted agents inhibit a wide range of kinase targets in addition to the VEGFRs, resulting in a range of adverse effects unrelated to efficient VEGF blockade. This article reviews recent advances in the development of the second-generation VEGFR TKIs, including the more selective VEGFR TKIs tivozanib and axitinib, and focuses on the potential benefits of novel inhibitors with improved potency and selectivity. |
Mendeley readers
The data shown below were compiled from readership statistics for 84 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 1% |
| Ireland | 1 | 1% |
| Unknown | 82 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 27% |
| Other | 10 | 12% |
| Student > Ph. D. Student | 10 | 12% |
| Student > Doctoral Student | 6 | 7% |
| Student > Bachelor | 5 | 6% |
| Other | 14 | 17% |
| Unknown | 16 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 27% |
| Agricultural and Biological Sciences | 18 | 21% |
| Biochemistry, Genetics and Molecular Biology | 9 | 11% |
| Chemistry | 5 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 4% |
| Other | 7 | 8% |
| Unknown | 19 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 October 2017.
All research outputs
#1,779,452
of 22,687,320 outputs
Outputs from Current Oncology Reports
#41
of 873 outputs
Outputs of similar age
#10,483
of 184,551 outputs
Outputs of similar age from Current Oncology Reports
#1
of 4 outputs
Altmetric has tracked 22,687,320 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 873 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 184,551 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them